These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 1362517)

  • 21. Dopamine D1 receptor mediation of the discriminative stimulus properties of SKF 38393.
    Cunningham KA; Callahan PM; Appel JB
    Eur J Pharmacol; 1985 Dec; 119(1-2):121-5. PubMed ID: 2935415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. D2 dopamine receptor-mediated mechanisms in the medial preoptic-anterior hypothalamus regulate effective defense behavior in the cat.
    Sweidan S; Edinger H; Siegel A
    Brain Res; 1991 May; 549(1):127-37. PubMed ID: 1680019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. One year of continuous treatment with haloperidol or clozapine fails to induce a hypersensitive response of caudate putamen neurons to dopamine D1 and D2 receptor agonists.
    Jiang LH; Kasser RJ; Altar CA; Wang RY
    J Pharmacol Exp Ther; 1990 Jun; 253(3):1198-205. PubMed ID: 1972751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of specific dopamine receptor subtypes in amphetamine discrimination.
    Smith FL; St John C; Yang TF; Lyness WH
    Psychopharmacology (Berl); 1989; 97(4):501-6. PubMed ID: 2567031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dopamine D1 receptor involvement in the discriminative-stimulus effects of SKF 81297 in squirrel monkeys.
    Rosenzweig-Lipson S; Bergman J
    J Pharmacol Exp Ther; 1993 Nov; 267(2):765-75. PubMed ID: 7902432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo assessment of release and metabolism of dopamine in the ventrolateral striatum of awake rats following administration of dopamine D1 and D2 receptor agonists and antagonists.
    See RE; Sorg BA; Chapman MA; Kalivas PW
    Neuropharmacology; 1991 Dec; 30(12A):1269-74. PubMed ID: 1686300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
    Sonsalla PK; Manzino L; Heikkila RE
    J Pharmacol Exp Ther; 1988 Oct; 247(1):180-5. PubMed ID: 2971797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies.
    Hu XT; White FJ
    Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dopamine stimulates growth hormone release from the pituitary of goldfish, Carassius auratus, through the dopamine D1 receptors.
    Wong AO; Chang JP; Peter RE
    Endocrinology; 1992 Mar; 130(3):1201-10. PubMed ID: 1347006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Respective roles of dopamine D2 and D3 receptors in food-seeking behaviour in rats.
    Duarte C; Biala G; Le Bihan C; Hamon M; Thiébot MH
    Psychopharmacology (Berl); 2003 Feb; 166(1):19-32. PubMed ID: 12525958
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dopamine D1 and D2 mediation of the discriminative stimulus properties of d-amphetamine and cocaine.
    Callahan PM; Appel JB; Cunningham KA
    Psychopharmacology (Berl); 1991; 103(1):50-5. PubMed ID: 2006243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of chronic treatment with selective agonists on the subtypes of dopamine receptors.
    Subramaniam S; Lucki I; McGonigle P
    Brain Res; 1992 Feb; 571(2):313-22. PubMed ID: 1351781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apomorphine affects cholecystokinin content via preferentially D1 or D2 dopamine receptor according to the regions of the rat brain.
    Yoshikawa T; Fukamauchi F; Shibuya H; Takahashi R
    Neuropeptides; 1989; 13(2):103-5. PubMed ID: 2567971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological characterization of the receptor mediating electrophysiological responses to dopamine in the rat medial prefrontal cortex: a microiontophoretic study.
    Sesack SR; Bunney BS
    J Pharmacol Exp Ther; 1989 Mar; 248(3):1323-33. PubMed ID: 2564893
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Latent inhibition is unaffected by direct dopamine agonists.
    Feldon J; Shofel A; Weiner I
    Pharmacol Biochem Behav; 1991 Feb; 38(2):309-14. PubMed ID: 1676170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of acetylcholine release by D1, D2 dopamine receptors in rat striatum under freely moving conditions.
    Ajima A; Yamaguchi T; Kato T
    Brain Res; 1990 Jun; 518(1-2):193-8. PubMed ID: 1975213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Striatal Fos expression is indicative of dopamine D1/D2 synergism and receptor supersensitivity.
    LaHoste GJ; Yu J; Marshall JF
    Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7451-5. PubMed ID: 8102797
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of uncoupling between D1- and D2-mediated motor behavior in rats depleted of dopamine as neonates.
    Byrnes EM; Bruno JP
    Dev Psychobiol; 1994 Sep; 27(6):409-24. PubMed ID: 8001729
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of selective drugs for dopaminergic D1 and D2 receptors on conditioned locomotion in rats.
    Mazurski EJ; Beninger RJ
    Psychopharmacology (Berl); 1991; 105(1):107-12. PubMed ID: 1684056
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Continuous treatment with the D2 dopamine receptor agonist quinpirole decreases D2 dopamine receptors, D2 dopamine receptor messenger RNA and proenkephalin messenger RNA, and increases mu opioid receptors in mouse striatum.
    Chen JF; Aloyo VJ; Weiss B
    Neuroscience; 1993 Jun; 54(3):669-80. PubMed ID: 8101360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.